Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, comments on the results of a study evaluating MB-106, a third-generation CD20-directed CAR-T therapy for the outpatient treatment of follicular lymphoma (FL). Dr Shadman notes high efficacy rates, with no reports of high-grade cytokine release syndrome (CRS), and no immune effector cell-associated neurotoxicity syndrome (ICANS).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.